Skip To Content

Study ID: Vertex VX15-661-113 CF Trial

Title:

Phase III study evaluating treatment with VX-661 in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation.

Description:
We would like you to take part in a research study because you have an illness called Cystic Fibrosis (“CF”). We are trying to learn more about VX-661, which is a new Study Drug being made by a company that makes medicines, Vertex Pharmaceuticals (“Vertex”).
Location:
Sioux Falls Region
Principal Investigator:
James Wallace, MD
Disease:
Lung
Stage:
Phase III
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.